Sensorion SAS (ALSEN) Price & Analysis

Compare

16 Followers

ALSEN Stock Chart & Stats

€0.30

€0.00(0.00%)

At close: Jan 09 4:00 PM EST

€0.30

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.15 - €0.69

Previous CloseN/A

Volume61.80K

Average Volume (3M)540.27K

Market Cap

€89.88M

Enterprise Value€48.35M

Total Cash (Recent Filing)€57.06M

Total Debt (Recent Filing)€1.55M

Price to Earnings (P/E)―

Beta1.33

Next Earnings

Mar 12, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding300,661,220

10 Day Avg. Volume740,129

30 Day Avg. Volume540,266

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)2.50

Price to Sales (P/S)27.15

P/FCF Ratio-8.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€4.00

Price Target Upside1233.33% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Acquisition InterestComparable early efficacy and a clean safety profile versus larger peers increase the likelihood of the company's hearing programs becoming attractive targets for pharmaceutical acquirers.

Clinical Data MilestonesSix-month follow-up data across treated patients could demonstrate durable and meaningful hearing gains that bolster regulatory discussions and investor confidence.

Pipeline AdvancementFiling a clinical trial application for the GJB2 gene therapy creates a pathway to capture a substantial hearing-loss segment and supports future value realization.

Bears Say

Competitive Approval RiskIf a competitor secures regulatory approval first, the investment case will depend more on demonstrating a clearly superior clinical outcome than on being first to market.

Direct Competitor ThreatRegeneron's advancing otoferlin program could capture significant U.S. and E.U. market share, constraining commercial prospects for competing therapies.

Market Size ConstraintsA relatively small addressable patient population raises questions about long-term revenue scale even if clinical success is achieved.

Sensorion SAS News

Sensorion: Differentiated OTOF and GJB2 Gene Therapy Pipeline Positions Company for Best-in-Class Outcomes and Attractive Risk-Reward Into 2026

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Sensorion SAS, boosting the price target to...

3d ago

Strong Buy Recommendation for Sensorion SAS Amid Promising Audiogene Study Results and Strategic Growth Prospects

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Sensorion SAS, retaining the price target of...

1M ago

Strategic Positioning of Sensorion SAS in the Gene Therapy Market for Hearing Loss

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Sensorion SAS, retaining the price target of...

3M ago

Sensorion SAS: Promising Prospects in Hearing Loss Gene Therapy Justify Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Sensorion SAS, with...

3M ago

Promising Progress in Sensorion SAS’s Gene Therapy Trials Drives Buy Rating

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Sensorion SAS. The associated price target...

6M ago

Promising Early Data from Sensorion’s SENS-501 Study Supports Buy Rating

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sensorion SAS on June 30 and set a...

7M ago

Optimistic Buy Rating for Sensorion SAS Amid Promising Gene Therapy Developments

Leerink Partners analyst Lili (Aurélie) Nsongo has maintained their bullish stance on RFM stock, giving a Buy rating...

7M ago

Sensorion SAS: Promising Growth Potential and Financial Stability Justify Buy Rating

Leerink Partners analyst Lili (Aurélie) Nsongo has maintained their bullish stance on RFM stock, giving a Buy rating...

10M ago

Sensorion SAS: Strong Financial Position and Promising Clinical Progress Justify Buy Rating

In a report released today, Clémence Thiers from Stifel Nicolaus maintained a Buy rating on Sensorion SAS (RFM...

10M ago

Promising Clinical Developments and Commercial Potential Drive Buy Rating for Sensorion SAS

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Sensorion SAS (RFM...

11M ago

ALSEN FAQ

What was Sensorion SAS’s price range in the past 12 months?

Sensorion SAS lowest stock price was €0.15 and its highest was €0.69 in the past 12 months.

What is Sensorion SAS’s market cap?

Sensorion SAS’s market cap is €89.88M.

When is Sensorion SAS’s upcoming earnings report date?

Sensorion SAS’s upcoming earnings report date is Mar 12, 2026 which is in 53 days.

How were Sensorion SAS’s earnings last quarter?

Sensorion SAS released its earnings results on Sep 17, 2025. The company reported -€0.05 earnings per share for the quarter, the consensus estimate of -€0.05 by €0.

Is Sensorion SAS overvalued?

According to Wall Street analysts Sensorion SAS’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sensorion SAS pay dividends?

Sensorion SAS does not currently pay dividends.

What is Sensorion SAS’s EPS estimate?

Sensorion SAS’s EPS estimate is -0.05.

How many shares outstanding does Sensorion SAS have?

Sensorion SAS has 300,661,220 shares outstanding.

What happened to Sensorion SAS’s price movement after its last earnings report?

Sensorion SAS reported an EPS of -€0.05 in its last earnings report, expectations of -€0.05. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Sensorion SAS?

Currently, no hedge funds are holding shares in FR:ALSEN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sensorion SAS

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.

Sensorion SAS (ALSEN) Earnings & Revenues

Historic Earnings Reports

ALSEN Stock 12 Month Forecast

Average Price Target

€4.00

▲(1233.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","5":"€5","-1":"-€1","0.5":"€0.5","3.5":"€3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.337,0.6187692307692307,0.9005384615384615,1.1823076923076923,1.464076923076923,1.7458461538461538,2.027615384615385,2.3093846153846154,2.5911538461538464,2.8729230769230774,3.154692307692308,3.4364615384615385,3.7182307692307695,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.337,0.6187692307692307,0.9005384615384615,1.1823076923076923,1.464076923076923,1.7458461538461538,2.027615384615385,2.3093846153846154,2.5911538461538464,2.8729230769230774,3.154692307692308,3.4364615384615385,3.7182307692307695,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.337,0.6187692307692307,0.9005384615384615,1.1823076923076923,1.464076923076923,1.7458461538461538,2.027615384615385,2.3093846153846154,2.5911538461538464,2.8729230769230774,3.154692307692308,3.4364615384615385,3.7182307692307695,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.636,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.628,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.602,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.318,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.318,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.347,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.318,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.337,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >